Guava Technologies announced last week its CellHealth Profiling technology, a series of methods designed to enable researchers to establish a baseline for funtional performance of cell cultures prior to running bioassays.
The technology enables profiling of key cellular indicators, such as apoptotic fraction and stage of apoptosis; viability; cell cycle; cell counts; transfection efficiency; or target expression levels, Guava said.
The assays, which can be performed on cell cultures including primary cells and blood cells, require only micro-volumes of cells and reagents, generating minimal waste, Guava said.
QTL Biosystems said last week that it has introduced its Universal Development Kit for kinase and phosphatase assays. The product release follows the recent launch of QTL’s serine/threonine and tyrosine kinase assay development kits, the company said.
Together, the products provide a platform for developing assays for the two categories of kinases that make up the human kinome, QTL said.
The Universal platform is based on QTL Lightspeed super-quenching technology, the company said. This technology eliminates expensive reagents and hazardous materials required for radiometric- and antibody-based technologies, and will enable the user to use as much as 50 percent less reagents and enzyme to develop an assay, QTL said.